Behcet's Disease Therapeutics

Behcet's Disease Therapeutics

Behçet's disease is a rare autoimmune disorder characterized by inflammation of blood vessels throughout the body, resulting in a wide range of symptoms. These may include recurrent oral ulcers, genital ulcers, skin lesions, eye inflammation, and joint pain. It can affect the gastrointestinal tract, central nervous system, and blood vessels. It's believed to involve a combination of genetic predisposition and environmental factors, such as infections or autoimmune triggers. A rising number of clinical trials and technological advancements are leading to the market's growth. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are driving the behcet’s disease therapeutics market globally.

The Behcet’s Disease Therapeutics Market is expected to grow at a steady rate of around 5.1% owing to the growing prevalence of behcet’s disease globally. For instance, according to the National Organization for Rare Disorders, Inc., behcet’s disease occurs most frequently in the Middle East and Asia. Turkey has the highest prevalence rate; Japan, Korea, China, Iran, and Saudi Arabia also have high prevalence rates. The disorder is the leading cause of blindness in Japan. Several factors, including a rising number of clinical trials to find effective treatment, and rising investments in healthcare departments are driving the market's growth during the forecast period. Apart from this, accelerated diagnosis of behcet’s disease therapeutics has resulted in higher demand for effective treatment procedures which are also driving this market of behcet’s disease therapeutics at a steady rate.

• Based on the treatment, the market is segmented into corticosteroids, immunosuppressive agents, and others. The immunosuppressive agents segment dominated the market in the year 2022 owing to the rising cases of severe Behcet’s disease. Immunosuppressive agents are an important component of the treatment regimen for Behçet's disease, for patients who do not respond adequately to corticosteroids alone or who require long-term management to prevent recurrent flares. These medications work by suppressing the overactive immune response responsible for inflammation in Behçet's disease. Thus, among the treatments, the immunosuppressive agents segment held a significant market share in 2022.
• Based on the route of administration, the market is segmented into oral, injectables, and others. The injectables segment is expected to grow with a high CAGR during the forecast period because of the rising number of clinical trials. For instance, in January 2023, Sohag University initiated a clinical trial to assess the safety and efficacy of adalimumab therapy for the treatment of Behcet's disease-related uveitis in adult patients at Sohag University Hospital. An injectable route of administration is utilized in Behçet's disease treatment, particularly for medications that require rapid onset of action, higher doses, or for individuals who cannot tolerate oral medications. Injectable administration allows for direct delivery of medications into the bloodstream, ensuring systemic distribution throughout the body. The growth of the treatment segment is driven by technological innovation, increasing disease prevalence, improved access to healthcare services, and a growing emphasis on early intervention and combination therapy approaches. Thus, the injectables segment among routes of administration is expected to witness a higher CAGR during the forecast period.
• Based on distribution channel, the market is categorized into hospitals pharmacies, retail pharmacies, and others. The hospital pharmacy segment dominated the market in the year 2022. Hospital pharmacies play a crucial role in Behçet's disease treatment by ensuring the availability, proper storage, preparation, and dispensing of medications used in the management of this condition. Hospital pharmacies cater to the needs of both inpatients and outpatients receiving treatment for Behçet's disease, providing comprehensive pharmaceutical care and support throughout the treatment process. Apart from this, the growing number of hospital set-ups is also propelling segmental growth. For instance, according to the American Hospital Association, there were about 6,093 hospitals in the U.S. in October 2022, which comprises community hospitals run by non-profit organizations as well as by state and local governments. Thus, hospitals held a significant share of the behcet’s disease therapeutics market in 2022.
• For a better understanding of the market adoption of behcet’s disease therapeutics, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with a high CAGR in the global behcet’s disease therapeutics market in the forecast period. Several factors such as a surge in the number of clinical trials being performed, enhanced accessibility, and diversified healthcare costs are driving the market’s growth during the forecast period. For instance, in December 2023, China-based Ganzhou Hemay Pharmaceutical Co., Ltd. initiated a clinical trial to study the efficacy and safety of Hemay005 tablets in patients with behçet's disease. Further, the increase in incidences of behcet’s disease is also having a positive impact on the market’s growth. There have been major awareness programs regarding rare diseases and product launches in the region. Thus, APAC is expected to witness a higher CAGR during the forecast period.
• Some of the major players operating in the market include AbbVie Inc.; Eisai Co., Ltd.; Ainos Inc.; Amgen Inc.; Mitsubishi Chemical Group Corporation; Bristol-Myers Squibb Company; Sanguine Biosciences; Takeda Pharmaceutical Company Limited; CELLTRION INC.; Cardinal Health.